Qinggan Yipi capsule ameliorates hepatic fibrosis in rats by down-regulating the TGF-β1/Smad2/3 signaling pathway and improving gut microbiota imbalance

Qinggan Yipi capsule ameliorates hepatic fibrosis in rats by down-regulating the TGF-β1/Smad2/3 signaling pathway and improving gut microbiota imbalance

Background and objectiveQinggan Yipi Capsule (QgYp) is a hospital preparation that has been used for many years in the treatment of chronic liver diseases. However, the mechanism of QgYp in ameliorating hepatic fibrosis (HF) remains unclear. This study aims to clarify the anti-liver fibrosis effect...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenjing Xue, Haiqing Liu, Ziheng Su, Siqi Wang, Junping Cheng, Yunzhi Pan, Lurong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
Qinggan Yipi capsule
hepatic fibrosis
TGF-β1/Smad2/3 signaling pathway
gut microbiota
network pharmacology
HSC-T6
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1525914/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items